Genprex® Nasdaq: GNPX 1 REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX FORWARD-LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forwardlooking statements. Such statements include, but are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to ______________ Commission file number: 001-38244 GENPREX, INC. (Exact name of registrant as specified in its charter) (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to ______________ Commission file number: 001-38244 GENPREX, INC. (Exact name of registrant as specified in its charter) (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38244 Genprex, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 90-0772347 (State or other jurisdiction of incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________________ to ______________ Commission file number: 001-38244 GENPREX, INC. (Exact name of registrant as specified in its charter) Delaware 90 - 0772347 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________________ to ______________ Commission file number: 001-38244 GENPREX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer i ...

Financial Performance - As of March 31, 2019, the company had an accumulated deficit of $31,983,537, having never generated revenue from product sales since inception [107]. - The company anticipates needing to raise additional capital to fund future operations, as it does not expect to generate revenue from product sales in the near term [110]. Expenses - Research and development expense increased to $508,042 for the three months ended March 31, 2019, compared to $51,621 for the same period in 2018, reflecting a rise of $456,421 driven by commercialization activities [102]. - General and administrative expense rose to $1,659,796 for the three months ended March 31, 2019, up from $634,063 in 2018, an increase of $1,025,733 attributed to higher headcount and operational activities [103]. - Net cash used in operating activities was $1,641,793 for the three months ended March 31, 2019, compared to $203,712 in 2018, marking an increase of $1,438,081 primarily due to higher general and administrative expenses [112]. - Net cash used in investing activities was $13,331 for the three months ended March 31, 2019, compared to $10,452 in 2018, an increase of $2,879 due to equipment purchases and patent prosecution [113]. - The company did not provide any cash from financing activities during the three months ended March 31, 2019, compared to $77,398 in 2018, due to no stock sales or debt issuance [114]. Cash Position - The company had $6,945,794 in cash as of March 31, 2019, with no outstanding debt [109][105]. Future Outlook - The company expects research and development expenses to increase as it advances its product candidates through clinical trials and seeks regulatory approval [98]. - The company has implemented all new accounting pronouncements that may affect its financial statements and does not foresee any material impact from other new accounting standards [87].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38244 Genprex, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 90-0772347 (State or Other Jurisdiction of Incorp ...